This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA
by Zacks Equity Research
Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.
DVAXNegative Net Change ALKSPositive Net Change DCPHPositive Net Change
biotechnology biotechs pharmaceuticals
Cincinnati Financial (CINF) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CINFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Zacks.com featured highlights include Las Vegas Sands, Voyager Therapeutics and nCino
by Zacks Equity Research
Las Vegas Sands, Voyager Therapeutics and nCino are part of the Zacks Screen of the Week article.
LVSNegative Net Change VYGRNegative Net Change NCNOPositive Net Change
biotechnology computers consumer-discretionary
Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy
by Zacks Equity Research
Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.
GSKPositive Net Change NVSPositive Net Change GILDPositive Net Change
biotechnology biotechs pharmaceuticals
Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants
by Zacks Equity Research
Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).
REGNPositive Net Change DVAXNegative Net Change BAYRYPositive Net Change SNDXPositive Net Change
biotechnology biotechs
Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update
by Zacks Equity Research
Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.
REGNPositive Net Change BMYPositive Net Change AMGNPositive Net Change GILDPositive Net Change KPRXNo Net Change
biotechnology biotechs
Zacks.com featured highlights Genmab, Hologic, ServiceNow and Splunk
by Zacks Equity Research
Genmab, Hologic, ServiceNow and Splunk have been highlighted in this Screen of The Week article.
HOLXPositive Net Change SPLKPositive Net Change NOWNegative Net Change GMABNegative Net Change
biotechnology
Exelixis (EXEL) Q4 Earnings Top, Revenues Beat on Cabometyx
by Zacks Equity Research
Exelixis (EXEL) beats earnings and sales estimates for the fourth quarter due to increased Cabometyx sales volume.
BMYPositive Net Change DVAXNegative Net Change EXELNegative Net Change SNDXPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Incyte's (INCY) Q4 Earnings, Revenues Top on Jakafi, Opzelura
by Zacks Equity Research
Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.
INCYPositive Net Change SNDXPositive Net Change
biotechnology biotechs earnings
Should You Buy Nice (NICE) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
NICENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL
by Zacks Equity Research
Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.
JNJPositive Net Change GILDPositive Net Change VRTXNegative Net Change INCYPositive Net Change EXELNegative Net Change
biotechnology biotechs earnings
Byline Bancorp (BY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
BYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology
by Zacks Equity Research
Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.
SNYNegative Net Change GSKPositive Net Change NVOPositive Net Change GILDPositive Net Change
biotechnology earnings
Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology earnings pharmaceuticals
Bunge (BG)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
BGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
American Airlines (AAL)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
AALPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Karuna (KRTX) to Obtain Global Rights to Goldfinch's Candidates
by Zacks Equity Research
Karuna Therapeutics (KRTX) announces a definitive agreement with Goldfinch Bio to acquire global rights to the latter's lead clinical-stage candidate, GFB-887 and TRPC4/5 channel candidates.
ACETNegative Net Change ADMANegative Net Change ETNBNegative Net Change
biotechnology biotechs
Time to Buy Cigna or Regeneron Stock Before Earnings?
by Shaun Pruitt
Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader market and economy declined.
REGNPositive Net Change CIPositive Net Change
biotechnology earnings finance genetics insurance investing medical
Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
SNYNegative Net Change NVSPositive Net Change NVOPositive Net Change
biotechnology biotechs pharmaceuticals
First Industrial Realty Trust (FR)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
5 Stocks With High ROE to Buy as Equity Markets Hold Promise
by Supriyo Bose
Jabil (JBL), Delta Air (DAL), AGNC Investment (AGNC), Hologic (HOLX) and Suzano (SUZ) are some of the stocks with high ROE to profit from as equity markets start 2023 on a positive note.
DALNegative Net Change HOLXPositive Net Change AGNCNegative Net Change JBLNegative Net Change SUZNegative Net Change
airlines biotechnology communications industrial-products reit
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
NVSPositive Net Change NVOPositive Net Change GILDPositive Net Change INCYPositive Net Change
biotechnology biotechs pharmaceuticals
Spruce Biosciences, Inc. (SPRB) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, HomeTrust Bancshares (HTBI)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
HTBIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Piedmont Lithium Inc. (PLL)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PLLNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines